Drugs in the Pipeline – Review ArticleThrombocytopenia During Prostacyclin Analogue Therapies of Pulmonary Arterial Hypertension—Possible Pathomechanisms and ImplicationsGrześk, Grzegorz MD, PhD; Karasek, Danuta PhD; Kusiak, Mateusz MDAuthor Information Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. Reprints: Mateusz Kusiak, MD, Department of Cardiology and Clinical Pharmacology, Faculty of Health Sciences Collegium Medicum, Nicolaus Copernicus University, ul. Ujejskiego 75, 85-168 Bydgoszcz, Poland (e-mail: email@example.com). The authors report no conflicts of interest. Received November 12, 2019 Accepted January 20, 2020 Journal of Cardiovascular Pharmacology: May 2020 - Volume 75 - Issue 5 - p 421-425 doi: 10.1097/FJC.0000000000000806 Buy Metrics Abstract Pulmonary arterial hypertension is a quite rare, but problematic disease in everyday cardiologists' practice. Prostanoids are the most important group of drugs used in this disease. One of the biggest problems encountered during treatment with analogs of prostacyclin is thrombocytopenia. Based on hematological guidelines we suggest common therapeutic schemes depending on the number of platelets or the severity of bleeding conducting the therapy. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.